Want to see VRCA full AI Analyst Report?
VRCA Stock Chart & Stats
$6.32
-$0.03(-3.87%)
At close: 4:00 PM EST
$6.32
-$0.03(-3.87%)
Day’s Range― - ―
52-Week Range$3.28 - $9.82
Previous CloseN/A
Volume115.12K
Average Volume (3M)41.23K
Market Cap
$113.72M
Enterprise Value$42.94M
Total Cash (Recent Filing)$20.60M
Total Debt (Recent Filing)$1.44M
Price to Earnings (P/E)―
Beta1.56
Next Earnings
Aug 11, 2026EPS Estimate
-0.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.56
Shares Outstanding17,178,785
10 Day Avg. Volume46,118
30 Day Avg. Volume41,228
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)3.58
Price to Sales (P/S)2.49
P/FCF Ratio-5.02
Enterprise Value/Market Cap0.38
Enterprise Value/Revenue1.16
Enterprise Value/Gross Profit1.29
Enterprise Value/Ebitda-3.78
Forecast
1Y Price Target
$16.00Price Target Upside153.16% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.58
Revenue Forecast (FY)$25.53M
Bulls Say, Bears Say
Bulls Say
Commercial Revenue & Unit MomentumSustained double-digit revenue growth and strong unit dispensation (+51.3% YoY) indicate durable clinical adoption in office settings. Continued organic volume expansion supports scale of sales processes, recurring in-office usage, and creates a foundation for margin leverage as fixed commercial costs are spread over higher volumes.
High Product-Level Gross MarginsVery high gross margins reflect attractive product economics for YCANTH, giving the company structural leeway to absorb elevated SG&A and R&D while moving toward profitability. Durable product margins support future operating leverage as revenues scale and reduce required incremental funding per dollar of revenue.
Partner-Funded International ExpansionA commercial partner launching in Japan and funding most Phase III costs materially reduces Verrica's capital burden and execution risk. This structural cost-sharing accelerates global development and market access while expanding TAM exposure without proportionate near-term cash outlays from Verrica.
Bears Say
Short Cash RunwayA runway into roughly Q1 2027 implies a likely financing need within about 12 months, creating execution and dilution risk. Reliance on external capital can constrain strategic flexibility, complicate long-term planning, and potentially delay or dilute investments in commercial expansion and late-stage trials if capital markets tighten.
Ongoing Unprofitability And Cash BurnSignificant negative operating and free cash flow reflects that current revenue does not yet cover elevated SG&A and R&D. Continued losses necessitate sustained growth or material cost control to reach self-funding operations; otherwise, persistent cash burn will perpetuate funding dependence and pressure on capital structure.
Structural Market Access & Adoption BarriersEntrenched clinical behaviors, pediatric access limitations, and PBM coverage gaps create a durable barrier to rapid penetration. Overcoming these requires sustained, potentially costly payer engagement and field expansion; slow adoption in key pediatric channels could cap addressable market growth and delay profitability.
Verrica Pharmaceuticals News
VRCA FAQ
What was Verrica Pharmaceuticals’s price range in the past 12 months?
Verrica Pharmaceuticals lowest stock price was $3.28 and its highest was $9.82 in the past 12 months.
What is Verrica Pharmaceuticals’s market cap?
Verrica Pharmaceuticals’s market cap is $113.72M.
When is Verrica Pharmaceuticals’s upcoming earnings report date?
Verrica Pharmaceuticals’s upcoming earnings report date is Aug 11, 2026 which is in 31 days.
How were Verrica Pharmaceuticals’s earnings last quarter?
Verrica Pharmaceuticals released its earnings results on May 12, 2026. The company reported -$0.45 earnings per share for the quarter, missing the consensus estimate of -$0.42 by -$0.03.
Is Verrica Pharmaceuticals overvalued?
According to Wall Street analysts Verrica Pharmaceuticals’s price is currently Undervalued.
Does Verrica Pharmaceuticals pay dividends?
Verrica Pharmaceuticals does not currently pay dividends.
What is Verrica Pharmaceuticals’s EPS estimate?
Verrica Pharmaceuticals’s EPS estimate is -0.4.
How many shares outstanding does Verrica Pharmaceuticals have?
Verrica Pharmaceuticals has 17,178,785 shares outstanding.
What happened to Verrica Pharmaceuticals’s price movement after its last earnings report?
Verrica Pharmaceuticals reported an EPS of -$0.45 in its last earnings report, missing expectations of -$0.42. Following the earnings report the stock price went up 3.077%.
Which hedge fund is a major shareholder of Verrica Pharmaceuticals?
Currently, no hedge funds are holding shares in VRCA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Verrica Pharmaceuticals Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$16.00 (153.16% Upside)
$16.00 (153.16% Upside)
Hedge Fund Trend
Decreased
By 325.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 4.1%
Last 30 Days ▼ 4.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-20.26%
12-Months-Change
Fundamentals
Return on Equity
-1136.50%
Trailing 12-Months
Asset Growth
-8.04%
Trailing 12-Months
Company Description
Verrica Pharmaceuticals
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma and other dermatological oncology indications. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum and common warts in Japan; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for use in malignant and pre-malignant dermatological indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
VRCA Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong commercial momentum for YCANTH — notably large year-over-year unit growth (51.3%), record monthly dispensing, a Japan launch and an advancing global Phase III program — and compelling Phase II clinical data for VP-315 (97% objective response, 86% tumor size reduction). These positive operational, regulatory and clinical developments are tempered by near-term financial pressures: a Q1 net loss, increased R&D and SG&A spend, modest gross-to-net variability, remaining access work particularly in pediatrics/PBMs, and a cash runway into Q1 2027 that implies a forthcoming financing need. Overall, the progress on product adoption, pipeline advancement, and international expansion outweigh the financial and access challenges reported.View all VRCA earnings summariesVRCA Stock 12 Month Forecast
Average Price Target
$16.00
▲(153.16% Upside)
Technical Analysis
Ownership Overview
47.49% Insiders
2.06% Mutual Funds
<0.01% Other Institutional Investors
48.70% Public Companies and
Individual Investors